Daryl C Drummond

Summary

Publications

  1. ncbi A novel assay for monitoring internalization of nanocarrier coupled antibodies
    Ulrik B Nielsen
    Department of Anesthesia, University of California San Francisco, San Francisco, CA 94110, USA
    BMC Immunol 7:24. 2006
  2. ncbi Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine
    Daryl C Drummond
    Hermes Biosciences, Inc, 61 Airport Blvd, Suite D, South San Francisco, CA 94080, USA
    J Pharmacol Exp Ther 328:321-30. 2009
  3. ncbi Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    J Pharm Sci 97:4696-740. 2008
  4. ncbi Development of a highly stable and targetable nanoliposomal formulation of topotecan
    Daryl C Drummond
    Hermes Biosciences, Inc, 61 Airport Boulevard, Suite D, South San Francisco, CA 94080, USA
    J Control Release 141:13-21. 2010
  5. ncbi Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
    Charles O Noble
    Hermes Biosciences Inc, South San Francisco, CA 94080, USA
    Cancer Chemother Pharmacol 64:741-51. 2009
  6. ncbi Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis
    David F Nellis
    SAIC-Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:221-32. 2005
  7. ncbi Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    Cancer Res 66:3271-7. 2006
  8. ncbi Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
    Dmitri B Kirpotin
    Hermes Biosciences Inc, South San Francisco, CA, USA
    Cancer Res 66:6732-40. 2006
  9. ncbi Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, Buck Institute for Age Research, Novato, California 94945, USA
    Clin Cancer Res 11:3392-401. 2005
  10. ncbi Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification
    David F Nellis
    SAIC-Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:205-20. 2005

Collaborators

  • John W Park
  • James D Marks
  • Bin Liu
  • Ulrik B Nielsen
  • Gary K Scott
  • Dmitri B Kirpotin
  • David F Nellis
  • Keelung Hong
  • Charles O Noble
  • Christopher C Benz
  • Steven L Giardina
  • Shelley C Perkins
  • Zexiong Guo
  • Mark E Hayes
  • Yi Shao
  • M Refaat Shalaby
  • Denise L Ekstrom
  • Thomas F Ouellette
  • George M Janini
  • John M Roach
  • Timothy F Ouellette
  • Shilpa R Shenoy
  • Trevor L Broadt
  • Richard Tsai
  • Jianwei Zhu
  • Robert Andersson

Detail Information

Publications11

  1. ncbi A novel assay for monitoring internalization of nanocarrier coupled antibodies
    Ulrik B Nielsen
    Department of Anesthesia, University of California San Francisco, San Francisco, CA 94110, USA
    BMC Immunol 7:24. 2006
    ..We have termed this methodology "Chelated Ligand Internalization Assay", or CLIA...
  2. ncbi Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine
    Daryl C Drummond
    Hermes Biosciences, Inc, 61 Airport Blvd, Suite D, South San Francisco, CA 94080, USA
    J Pharmacol Exp Ther 328:321-30. 2009
    ..8 mg VRL/kg for nanoliposomal vinorelbine. Our results demonstrate that a highly active, stable, and long-circulating liposomal vinorelbine can be prepared and warrants further study in the treatment of cancer...
  3. ncbi Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    J Pharm Sci 97:4696-740. 2008
    ....
  4. ncbi Development of a highly stable and targetable nanoliposomal formulation of topotecan
    Daryl C Drummond
    Hermes Biosciences, Inc, 61 Airport Boulevard, Suite D, South San Francisco, CA 94080, USA
    J Control Release 141:13-21. 2010
    ....
  5. ncbi Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
    Charles O Noble
    Hermes Biosciences Inc, South San Francisco, CA 94080, USA
    Cancer Chemother Pharmacol 64:741-51. 2009
    ....
  6. ncbi Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis
    David F Nellis
    SAIC-Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:221-32. 2005
    ....
  7. ncbi Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    Cancer Res 66:3271-7. 2006
    ..This study shows that intraliposomal stabilization of CPT-11 using a polymeric or highly charged, nonpolymeric polyanionic trapping agent results in a markedly active antitumor agent with low toxicity...
  8. ncbi Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
    Dmitri B Kirpotin
    Hermes Biosciences Inc, South San Francisco, CA, USA
    Cancer Res 66:6732-40. 2006
    ..Immunoliposomes capable of selective internalization in cancer cells in vivo may provide new opportunities for drug delivery...
  9. ncbi Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, Buck Institute for Age Research, Novato, California 94945, USA
    Clin Cancer Res 11:3392-401. 2005
    ....
  10. ncbi Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification
    David F Nellis
    SAIC-Frederick, Inc, National Cancer Institute at Frederick, PO Box B, Frederick, Maryland 21702, USA
    Biotechnol Prog 21:205-20. 2005
    ..Residual endotoxin, rProtein A, and genomic DNA, were at acceptable levels. This study successfully addressed a necessary step in the scale-up of immunoliposome-encapsulated therapeutics...
  11. ncbi Clinical development of histone deacetylase inhibitors as anticancer agents
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    Annu Rev Pharmacol Toxicol 45:495-528. 2005
    ....